Valuation: Pfizer Inc

Market Cap 138B 121B 111B 103B 196B 13,193B 199B 1,335B 523B 6,478B 519B 508B 22,440B P/E 2026 *
12.3x
P/E 2027 * 12.8x
Enterprise Value 188B 164B 151B 140B 266B 17,898B 270B 1,812B 710B 8,789B 704B 689B 30,445B EV / Sales 2026 *
3.04x
EV / Sales 2027 * 3.06x
Free-Float
59.06%
Yield 2026 *
7.22%
Yield 2027 * 7.19%

Last Transcript: Pfizer Inc

Manager TitleAgeSince
Chief Executive Officer 64 2018-12-31
Director of Finance/CFO 60 2022-05-01
Chief Tech/Sci/R&D Officer - 2006-12-31
Director TitleAgeSince
Director/Board Member 68 2007-08-31
Director/Board Member 62 2013-09-26
Chairman 64 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.61%-0.97%+50.30%+162.24% 1,085B
-0.96%-0.45%+63.71%+61.85% 624B
-1.41%-3.13%+26.55%+83.49% 442B
+0.33%-1.17%+27.98%+26.90% 332B
-3.89%-11.22%+20.78%+26.07% 277B
-0.02%-2.85%+25.27%+44.88% 282B
+0.66%-1.42%-29.26%-39.30% 217B
-0.03%-0.56%+21.31%+62.14% 196B
-3.10%+1.29%+14.61%+73.44% 167B
Average -1.30%-1.86%+24.59%+55.75% 402.44B
Weighted average by Cap. -1.56%-1.06%+35.48%+81.80%

Financials

2026 *2027 *
Net sales 61.74B 54.01B 49.81B 46.09B 87.47B 5,893B 88.93B 596B 234B 2,894B 232B 227B 10,025B 59.36B 51.92B 47.88B 44.3B 84.09B 5,666B 85.5B 573B 225B 2,782B 223B 218B 9,637B
Net income 10.67B 9.33B 8.6B 7.96B 15.11B 1,018B 15.36B 103B 40.39B 500B 40.04B 39.18B 1,732B 10.27B 8.98B 8.28B 7.66B 14.55B 980B 14.79B 99.2B 38.88B 481B 38.55B 37.71B 1,667B
Net Debt 49.3B 43.13B 39.77B 36.8B 69.84B 4,706B 71.01B 476B 187B 2,311B 185B 181B 8,004B 43.17B 37.76B 34.82B 32.22B 61.16B 4,120B 62.18B 417B 163B 2,023B 162B 159B 7,009B
Logo Pfizer Inc
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-